Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 833 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Graft-Versus-Host-Disease Clear all
Terminated Phase 2 Interventional Results available

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT00720629
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Visilizumab, Tacrolimus, Methotrexate, Antithymocyte globulin (ATG)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

NCT03657160
View directory record Official record
Conditions
Hematopoietic Stem Cells
Interventions
Vedolizumab Placebo, Vedolizumab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)

NCT02193880
View directory record Official record
Conditions
Hematologic Neoplasms, Graft-Versus-Host Disease
Interventions
Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
Device
Lead sponsor
Ayman Saad
Other
Eligibility
19 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

NCT00755781
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease

NCT00391170
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Topical Dexamethasone, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years to 110 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

NCT02841995
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Belumosudil (KD025)
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Duarte, California • Minneapolis, Minnesota • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT00031824
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
cyclosporine, hydroxychloroquine, prednisone, tacrolimus
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 29 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
89
States / cities
Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine

NCT03337620
View directory record Official record
Conditions
Headache, Migraine
Interventions
Tx360
Device
Lead sponsor
Tian Medical Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
New Haven, Connecticut • Stamford, Connecticut • Fort Gordon, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

NCT02296424
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis (SJIA)
Interventions
ACZ885 150 mg (Canakinumab)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 20 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 7, 2026, 4:53 AM EDT
Terminated Not applicable Interventional Results available

Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy

NCT04521777
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
Exercise Intervention, Physical Performance Testing, Questionnaire Administration
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT03790332
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
1 Year to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Duarte, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer

NCT00005785
View directory record Official record
Conditions
Hematologic Neoplasm, HIV Infection
Interventions
GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 2Phase 3 Interventional

Dose of Spinal Manipulation for Chronic Low Back Pain

NCT00376350
View directory record Official record
Conditions
Low Back Pain
Interventions
Spinal Manipulation, Light Massage, Pulsed Ultrasound
Procedure
Lead sponsor
University of Western States
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 7, 2026, 4:53 AM EDT
Recruiting Not applicable Interventional

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

NCT04337515
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease
Interventions
CliniMacs®
Device
Lead sponsor
Christopher Dvorak
Other
Eligibility
Up to 30 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 7, 2026, 4:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Haploidentical PBMC Transplant for Severe Congenital Anemias

NCT00977691
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
PBSC Transplant, Alemtuzumab, Sirolimus, Cyclophosphamide, Low Dose Irradiation
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 7, 2026, 4:53 AM EDT
Recruiting Not applicable Interventional

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

NCT07535008
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions
Dental Cleaning, Dental Plaque sampling
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Functional Magnetic Resonance Imaging (fMRI) and Robot-Assisted Practice of Activities of Daily Living

NCT00878085
View directory record Official record
Conditions
Hemiparesis, Ischemic Stroke, Chronic
Interventions
Robot Therapy Device, Occupational Therapy
Device · Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
30 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 7, 2026, 4:53 AM EDT
Recruiting Phase 1 Interventional

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

NCT05443425
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
Interventions
Cholestyramine, Leflunomide, Steroid Therapy
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 7, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

NCT07354074
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Interventions
Asciminib single agent
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 7, 2026, 4:53 AM EDT
Active, not recruiting Not applicable Interventional

Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

NCT04922736
View directory record Official record
Conditions
Scleroderma, Systemic, Morphea, Graft Vs Host Disease
Interventions
UVA-1 Phototherapy
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 7, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Combining Medications to Enhance Depression Outcomes

NCT00590863
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI + placebo, Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Harbor City, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 7, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

Ibrutinib and Rituxan for Chronic GVHD

NCT04235036
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Rituximab, Ibrutinib
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 7, 2026, 4:53 AM EDT
Withdrawn Phase 1 Interventional

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

NCT02526329
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
donor regulatory T lymphocytes, laboratory biomarker analysis
Biological · Other
Lead sponsor
Everett Meyer
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 7, 2026, 4:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)

NCT01530256
View directory record Official record
Conditions
Acute GvHD
Interventions
ALD518
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Duarte, California • Maywood, Illinois • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 7, 2026, 4:53 AM EDT